Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals reported a net loss of $(43.4) million for the second quarter of 2026, an increase from $(41.4) million in the prior year period. Year-to-date net loss also widened to $(84.7) million. The company's cash and cash equivalents significantly decreased to $49.3 million as of June 30, 2026, though marketable securities saw a substantial increase. Additionally, Amylyx reached an agreement in principle to settle a class action lawsuit for $6.5 million, with a significant portion covered by insurance.

Amylyx Pharmaceuticals reported a Q2 2026 net loss of $43.4 million, or $0.39 per share. The company announced the completion of the final study visit for the last participant in its pivotal Phase 3 LUCIDITY trial for avexitide, with topline data expected in late August or early September 2026. Amylyx anticipates its cash runway will fund operations into 2028.

Amylyx Pharmaceuticals reported a net loss of $41.3 million for Q1 2026, an increase from $35.9 million in Q1 2025. Despite the higher net loss, net loss per share improved to $(0.37) due to a significant increase in weighted-average shares outstanding. The company ended the quarter with $229.1 million in cash and cash equivalents. Additionally, Amylyx reached an agreement in principle to settle a class action lawsuit for $6.5 million, largely covered by insurance, while facing multiple ongoing derivative complaints.

Amylyx Pharmaceuticals reported a net loss of $41.3 million, or $0.37 per share, for the first quarter ended March 31, 2026, compared to a net loss of $35.9 million, or $0.42 per share, in the prior year. The company announced that topline data from the pivotal Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) is on track for Q3 2026, with potential commercial launch in 2027 if approved. Amylyx also confirmed a cash runway extending into 2028, supporting operations through potential avexitide commercialization. Additionally, enrollment was completed for the LUCIDITY trial and Cohort 2 of the Phase 1 LUMINA trial for AMX0114 in ALS.